1. Home
  2. Directory
  3. Oklahoma
  4. City
  5. Nurse Practitioner
  6. NPI Profile
  7. Prescriptions 1962887653

KACY LYNN ADERHOLD APRN-CNS
Prescription History 1962887653
Nurse Practitioner in Oklahoma City, OK


Quality Rating: 71.66 out of 100 score

NPI Status: Active since July 23, 2015

Contact Information

1000 N LINCOLN BLVD
OKLAHOMA CITY, OK
ZIP 73104
Phone: (405) 271-1000
Fax: (000) 000-0000

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for KACY LYNN ADERHOLD APRN-CNS, an active Nurse Practitioner specialist practicing in Oklahoma City, OK. Our medical registry currently tracks 10 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 271 documented patient claims. Among these therapy options, the most frequently utilized medication is Trulicity, which accounts for 64 claims alone.

Medication Index

Humalog Kwikpen U-100

Generic Formulation: Insulin LisproSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 19
30-Day Fills 41.6
Days Supply 1,230
OK State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills41.0
Peer Average Days Supply1,162
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $27,549.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,450.00

State Avg Cost Per Claim

$908.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Insulin that has been modified so that the B-chain contains a LYSINE at position 28 instead of a PROLINE and a PROLINE at position 29 instead of a LYSINE. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.

Therapeutic Applications

Insulin lispro is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin lispro is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. Insulin lispro starts working faster and lasts for a shorter time than regular insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. This medication is usually used with a medium- or long-acting insulin product. Insulin lispro may also be used with other oral diabetes medications (such as sulfonylureas like glyburide or glipizide).

Insulin Lispro Kwikpen U-100

Generic Formulation: Insulin LisproSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 11
30-Day Fills 20.0
Days Supply 600
OK State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills27.9
Peer Average Days Supply729
Conservative Utilization

This provider writes prescriptions for this formulation 42.1% less frequently than the standard regional baseline metric for practitioners inside OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,282.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$298.39

State Avg Cost Per Claim

$216.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Insulin that has been modified so that the B-chain contains a LYSINE at position 28 instead of a PROLINE and a PROLINE at position 29 instead of a LYSINE. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.

Therapeutic Applications

Insulin lispro is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin lispro is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. Insulin lispro starts working faster and lasts for a shorter time than regular insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. This medication is usually used with a medium- or long-acting insulin product. Insulin lispro may also be used with other oral diabetes medications (such as sulfonylureas like glyburide or glipizide).

Levothyroxine Sodium

Generic Formulation: Levothyroxine SodiumSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 19
30-Day Fills 57.0
Days Supply 1,710
OK State Average Benchmarks
Peer Average Claims153.0
Peer Average 30-Day Fills341.1
Peer Average Days Supply9,928
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 87.6% less volume than the regional standard for practitioners inside OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $435.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.92

State Avg Cost Per Claim

$16.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.

Therapeutic Applications

Levothyroxine is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally produced by the thyroid gland. Low thyroid hormone levels can occur naturally or when the thyroid gland is injured by radiation/medications or removed by surgery. Having enough thyroid hormone is important for maintaining normal mental and physical activity. In children, having enough thyroid hormone is important for normal mental and physical development. This medication is also used to treat other types of thyroid disorders (such as thyroid cancer). This medication should not be used to treat infertility unless it is caused by low thyroid hormone levels.

Metformin Hcl Er

Generic Formulation: Metformin HclSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 28
30-Day Fills 64.0
Days Supply 1,913
OK State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills111.5
Peer Average Days Supply3,324
Conservative Utilization

This provider writes prescriptions for this formulation 45.1% less frequently than the standard regional baseline metric for practitioners inside OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $702.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.08

State Avg Cost Per Claim

$10.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)

Therapeutic Applications

Metformin is used with a proper diet and exercise program and possibly with other medications to control high blood sugar. It is used in patients with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Metformin works by helping to restore your body's proper response to the insulin you naturally produce. It also decreases the amount of sugar that your liver makes and that your stomach/intestines absorb.

Nano 2nd Gen Pen Needle

Generic Formulation: Pen Needle, DiabeticSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 23
30-Day Fills 64.6
Days Supply 1,938
OK State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills41.9
Peer Average Days Supply1,239
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,866.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$124.65

State Avg Cost Per Claim

$99.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Ozempic

Generic Formulation: SemaglutideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 34
30-Day Fills 46.1
Days Supply 1,330
OK State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills57.6
Peer Average Days Supply1,661
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $45,809.39 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,347.34

State Avg Cost Per Claim

$1,165.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Semaglutide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Semaglutide is also used in people with type 2 diabetes and heart disease to lower the risk of death from heart attack or stroke. Semaglutide is similar to a natural hormone in your body (incretin). It works by causing insulin release in response to high blood sugar (such as after a meal) and decreasing the amount of sugar your liver makes. If you use insulin, semaglutide is not a substitute for insulin treatment.

Tresiba Flextouch U-100

Generic Formulation: Insulin DegludecSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 15
30-Day Fills 48.1
Days Supply 1,444
OK State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills40.9
Peer Average Days Supply1,173
Conservative Utilization

This provider writes prescriptions for this formulation 34.8% less frequently than the standard regional baseline metric for practitioners inside OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,660.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$644.01

State Avg Cost Per Claim

$669.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Insulin degludec is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin degludec is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. It acts longer than regular insulin, providing a low, steady level of insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. Insulin degludec may be used with a shorter-acting insulin product. It may also be used alone or with other diabetes drugs.

Tresiba Flextouch U-200

Generic Formulation: Insulin DegludecSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 46
30-Day Fills 122.3
Days Supply 3,664
OK State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills51.5
Peer Average Days Supply1,490
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 58.6% higher than the standard regional baseline profile for OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $65,954.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,433.79

State Avg Cost Per Claim

$1,247.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Insulin degludec is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin degludec is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. It acts longer than regular insulin, providing a low, steady level of insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. Insulin degludec may be used with a shorter-acting insulin product. It may also be used alone or with other diabetes drugs.

Trulicity

Generic Formulation: DulaglutideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 64
30-Day Fills 109.4
Days Supply 3,206
OK State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills57.6
Peer Average Days Supply1,659
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 56.1% higher than the standard regional baseline profile for OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $111,553.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,743.03

State Avg Cost Per Claim

$1,332.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dulaglutide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. This medication is also used to lessen the risk of a major cardiovascular event (such as heart attack or stroke) in people who already have, or are at high risk for heart/blood vessel disease. Dulaglutide is similar to a natural hormone in your body (incretin). It works by causing insulin release in response to high blood sugar (such as after a meal) and by decreasing the amount of sugar your liver makes. Dulaglutide is not a substitute for insulin if you need insulin treatment.

Xultophy 100-3.6

Generic Formulation: Insulin Degludec/LiraglutideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 12
30-Day Fills 15.1
Days Supply 454
OK State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills24.2
Peer Average Days Supply702
Conservative Utilization

This provider writes prescriptions for this formulation 29.4% less frequently than the standard regional baseline metric for practitioners inside OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $15,253.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,271.16

State Avg Cost Per Claim

$1,477.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is a combination of insulin degludec and liraglutide and is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin degludec is a man-made product that is similar to human insulin. It acts longer than regular insulin, providing a low, steady level of insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. Liraglutide is similar to a natural hormone in your body (incretin). It works by causing insulin release in response to high sugar levels (such as after a meal) and decreasing the amount of sugar your liver makes.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like KACY LYNN ADERHOLD APRN-CNS provides transparency into local medical care patterns within Oklahoma City, OK.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Nurse Practitioner** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.